XXXX : AUA Guideline.

@entity1 @entity545 @entity1726
PURPOSE: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of @entity545 . MATERIALS AND METHODS: A systematic review of the literature using the PubMed  , EMBASE   and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of @entity1726 . The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria. RESULTS: The systematic review was used to create guideline statements regarding treatment of @entity1726 . When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to @entity1 . Additional consensus statements related to the diagnosis of @entity1726 are provided as Clinical Principles and Expert Opinions due to insufficient published evidence. CONCLUSIONS: There is a continually expanding literature on @entity1726 ; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular @entity1 is best determined by the individual clinician and @entity1 in the context of that @entity1 's history, values, and goals for treatment. As the science relevant to @entity1726 evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.
